Proactive - Interviews for investors

Condor Gold PLC (AIM:CNR, TSX:COG, OTC:CNDGF) CEO Mark Child speaks with Proactive's Stephen Gunnion about the heightened interest in the company’s gold assets in Nicaragua, driven by the current high gold price. Child shared insights from recent industry conferences, where he met with several potential buyers. He highlighted the significance of having fully permitted mining projects like Condor Gold’s La India, which has seen several non-binding offers, including one from a Chinese group.

Child emphasised how Condor's feasibility studies demonstrate significant improvements in project economics, driven by gold prices of $2,400 per ounce or higher. According to Child, the project’s Net Present Value (NPV) and EBITDA have doubled, making it more attractive to buyers. He also underlined the importance of strategic patience in securing a deal that benefits shareholders.

Child remains optimistic, stating that Condor Gold’s fully permitted project and ongoing land acquisitions in Nicaragua position the company for a favourable outcome in negotiations.

Remember to like this video, subscribe to the channel, and enable notifications for more updates from Proactive.

#CondorGold #GoldMining #MarkChild #GoldPrices #NicaraguaMining #MiningInvestments #PreciousMetals #GoldProject #MiningDeals #GoldExploration

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Aurrigo International PLC CEO David Keene talked with Proactive's Stephen Gunnion about the company's efforts to revolutionise airport operations with electric and autonomous vehicles. Keene explained that Aurrigo is focusing on airside solutions, primarily for baggage and cargo handling. The company works with major clients like Changi Airport in Singapore, Cincinnati in the US, and Schiphol in the Netherlands, addressing key post-COVID challenges such as labour shortages and operational efficiency.

Discussing future growth, Keene highlighted that Aurrigo's solutions could be deployed in over 600 airports worldwide, with their electric and autonomous technology offering seamless scalability across different airport sizes. He also mentioned that Aurrigo's latest vehicle, the Auto-Dolly Tug, provides a fully autonomous solution for moving baggage containers across airport runways, further advancing automation in the aviation industry.

Looking ahead, Keene emphasised the company's focus on key markets in Europe, North America, and Southeast Asia, noting that airports are transitioning from diesel and petrol-driven vehicles to electric ones, aligning with global carbon reduction goals.

For more insights from David Keene and other industry leaders, be sure to like this video, subscribe to Proactive's YouTube channel, and enable notifications for the latest updates!

#Aurrigo #AirportAutomation #AutonomousVehicles #ElectricVehicles #AviationTech #DavidKeene #CargoHandling #BaggageSolutions #SustainableAirports #ProactiveInvestors #ElectricFuture

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

CleanTech Lithium PLC (AIM:CTL, OTCQX:CTLHF) executive chairman Dr Steve Kesler takes Proactive's Stephen Gunnion through the company's latest advancements in its Laguna Verde project, following significant news from the Chilean government. The project has been prioritised under Chile's special lithium operating contract (CEOL) process, positioning CleanTech Lithium as a frontrunner in the region.

Kesler explained, “We’re now in a very good position for our shareholders... there’s a clear line of sight for the obtaining of the CEOL,” outlining how the company's strong community ties, established mining licenses, and unique technological approach have placed it ahead in securing the contract. CleanTech Lithium aims to begin production by 2027, making it potentially the first private-sector lithium producer in Chile.

With the Chilean government’s plans to increase lithium output by 70% by 2030, CleanTech Lithium’s Laguna Verde is set to play a pivotal role in the nation’s energy transition. The company also highlighted its commitment to environmental sustainability, utilising Direct Lithium Extraction (DLE) technology to minimise water usage, ensuring community support.

For more videos like this, make sure to give this video a like, subscribe to Proactive's YouTube channel, and enable notifications for future content.

#CleanTechLithium #LithiumMining #ChileLithium #GreenEnergy #SustainableMining #LagunaVerde #LithiumProduction #DLETechnology #MiningNews #EnergyTransition #LithiumBatteries #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Graft Polymer (UK) PLC (LSE:GPL) chairman Dennis Purcell speaks with Proactive's Stephen Gunnion about his new role and the company’s future in the biotechnology space. With over 40 years of experience in life sciences, first as an investment banker and then as a venture capitalist, Purcell brings valuable expertise to Graft Polymer, especially in mergers, acquisitions, and partnerships.

During the interview, Purcell emphasised the opportunities in addressing unmet medical needs, particularly in mental health. "Mental health is going to be one of the areas that we must tackle going forward," he said, highlighting the potential for advancements in treatment-resistant conditions like PTSD, depression, and addiction.

He also praised Graft Polymer’s drug delivery and polymer modification technologies, which he believes will be critical in enhancing drug absorption and effectiveness, particularly for mental health treatments. Purcell sees significant potential for Graft Polymer to form new partnerships with biotechnology and pharmaceutical companies to drive growth.

For more insights, visit Proactive’s YouTube channel, give this video a like, subscribe, and enable notifications for future content.

#GraftPolymer #BiotechInnovation #DrugDelivery #MentalHealthSolutions #DennisPurcell #Biotechnology #PolymerTechnology #HealthcareInnovation #PharmaTech #ProactiveInvestors

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Electric Guitar PLC (AIM:ELEG) CEO John Regan talked with Proactive's Stephen Gunnion about the company's latest initiatives, including the development of a loyalty app that leverages open banking data. According to Regan, the app allows users to access their bank data, identify opportunities to save money and take advantage of offers like cheaper energy providers.

“They can analyse open banking data, and with a single click, you can find a cheaper energy provider,” said Regan. The app is repurposed to act as a loyalty scheme for Electric Guitar’s clients, offering valuable insights into consumer behaviour.

Regan also discussed the company's recent activities in Singapore, including a new campaign with Mediacorp. Through this collaboration, Electric Guitar aims to help Mediacorp better understand its audience by gathering data through interactive games, boosting user engagement with its media platforms. The successful test results with Mediacorp have led to the rollout of these innovations across its media streaming services.

For more updates and insights from Electric Guitar PLC, make sure to like this video, subscribe to the Proactive YouTube channel, and hit the notification bell for future content.

#ElectricGuitarPLC #LoyaltyApp #OpenBanking #JohnRegan #AI #BankingData #MediaCorp #CustomerEngagement #SaaS #TechInnovation #Fintech #DigitalTransformation #EnergySavings

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s significant presence at the 40th ECTRIMS Congress in Copenhagen. Muehler emphasised the importance of this event for Immunic, particularly with vidofludimus calcium, its promising treatment for multiple sclerosis (MS).

This year marked a milestone for Immunic as it had its own booth for the first time, garnering substantial attention. Muehler detailed the four posters presented, including data from the Phase 2 CALLIPER trial for progressive MS and the drug's potential effect on neuroprotection and MS fatigue. One key area of focus was the potential impact of vidofludimus calcium on MS fatigue, a symptom that severely affects over half of MS patients.

He also highlighted the broader relevance of vidofludimus calcium's antiviral properties and its potential effect on EBV reactivation, a known contributor to fatigue. The enthusiasm for Immunic’s ongoing Phase 3 and Phase 2 trials shows the company’s commitment to addressing unmet needs in MS treatment. With crucial milestones like the CALLIPER trial readout scheduled for April 2025, Immunic continues to play a significant role in advancing MS research.

For more interviews and updates on the latest in biotech and pharmaceuticals, be sure to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for future content.

#Immunic #MultipleSclerosis #ECTRIMS2024 #VidofludimusCalcium #MSFatigue #Phase3Trials #Biotech #Neuroprotection #MSResearch #EBV #MSAwareness #CALLIPERtrial #ProgressiveMS

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Majestic Corporation Plc (AQSE:MCJ) founder and CEO Peter Lai speaks with Proactive's Stephen Gunnion about the company’s role in revolutionising recycling within the precious and base metals sector. Founded in 2018, Majestic Corporation specialises in sustainable circular economy solutions, focusing on recycling valuable metals from electronic waste. Lai explained the company’s three core sources for extracting materials like gold, copper, and platinum—computer circuit boards, electronic goods, and industrial waste.

Lai highlighted how the recycling industry is projected to grow significantly, driven by increasing demand for materials due to upgrades in infrastructure like data centres and consumer electronics. Majestic’s recent conditional acquisition of Telecycle strengthens its position in the UK, one of the world’s largest producers of waste electrical and electronic equipment (WEEE).

Lai emphasised that recycling not only offers a cost-effective alternative to mining but also supports sustainability efforts by reintroducing valuable metals into the supply chain. He mentioned that recycling is more crucial than ever, with high interest rates and macroeconomic challenges slowing the development of new mining operations. Majestic’s acquisition of Telecycle marks a major step forward in the UK market.

Visit Proactive's YouTube channel for more interviews like this. Don't forget to like, subscribe, and turn on notifications to stay updated on future content!

#MajesticCorporation #RecyclingInnovation #Sustainability #CircularEconomy #PreciousMetals #TelecycleAcquisition #WEEERecycling #Ewaste #UKRecycling #PeterLai #ProactiveInvestors

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell takes Proactive's Stephen Gunnion through the company's interim results and key highlights across the company's diabetes and obesity programs. Howell emphasised advancements in its proprietary pipeline, including significant clinical data on AT278, an ultra-concentrated, ultra-rapid-acting insulin shown to be superior in patients with Type 1 and Type 2 diabetes. She also discussed their progress with a new oral GLP-1 formulation in collaboration with TRx Biosciences and the promising future studies planned for 2025.

The conversation also highlighted Arecor's strategic partnership with Medtronic to develop a stable, long-wear insulin for implantable pumps, aimed at a vulnerable patient group requiring advanced insulin therapies. Howell noted the importance of licensing deals, like AT220, which are driving revenue through royalties and validating their Arestat technology. The company's partnerships with major pharmaceutical firms like Eli Lilly, Sanofi, and Medtronic continue to be critical to its success.

In closing, Howell expressed confidence in Arecor’s strategy and highlighted its potential for creating long-term value. She also provided updates on the specialty pharmaceutical business Tetris Pharma, particularly their glucagon pen Ogluo®, for severe hypoglycemia, which is showing market growth in the UK and Germany.

Stay tuned for more updates from Arecor Therapeutics and don't forget to like the video, subscribe to Proactive's channel, and enable notifications for the latest interviews and insights.

#ArecorTherapeutics #DiabetesResearch #ObesityTreatment #InsulinPump #PharmaPartnerships #GLP1 #Medtronic #TetrisPharma #Biotech #HealthcareInnovations

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden takes Proactive's Stephen Gunnion through the progress made in the six months to June 30 and upcoming milestones. Marsden provided updates on Synairgen's antiviral treatment, SNG001, and plans for a trial in mechanically ventilated patients suffering from severe viral lung infections.

Marsden also touched on recent changes in Synairgen's leadership, including the appointment of Mark Parry-Billings as the new chairman. Parry-Billings, who brings extensive experience in inhaled anti-infective treatments, is set to take on his role in October, a move Marsden sees as a significant step forward for the company.

Looking ahead, Marsden mentioned that more details on the phase II trial of its lead asset and its funding would be released soon. As Synairgen progresses, the company remains focused on improving outcomes for patients with severe viral infections.

Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications to stay updated with Synairgen’s latest developments.

#Synairgen #SNG001 #ClinicalTrials #VentilatorCare #AntiviralTreatment #BiotechInnovation #PharmaceuticalUpdates #RichardMarsden #ProactiveInvestors #HealthcareInnovation

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnewsSynairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden takes Proactive's Stephen Gunnion through the progress made in the six months to June 30 and upcoming milestones. Marsden provided updates on Synairgen's antiviral treatment, SNG001, and plans for a trial in mechanically ventilated patients suffering from severe viral lung infections.

Marsden also touched on recent changes in Synairgen's leadership, including the appointment of Mark Parry-Billings as the new chairman. Parry-Billings, who brings extensive experience in inhaled anti-infective treatments, is set to take on his role in October, a move Marsden sees as a significant step forward for the company.

Looking ahead, Marsden mentioned that more details on the phase II trial of its lead asset and its funding would be released soon. As Synairgen progresses, the company remains focused on improving outcomes for patients with severe viral infections.

Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications to stay updated with Synairgen’s latest developments.

#Synairgen #SNG001 #ClinicalTrials #VentilatorCare #AntiviralTreatment #BiotechInnovation #PharmaceuticalUpdates #RichardMarsden #ProactiveInvestors #HealthcareInnovation

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

EMV Capital (AIM:EMVC) Plc CEO Ilian Iliev joins Proactive's Stephen Gunnion with details of the company’s rebranding and its evolving investment strategy.

Iliev explained the rationale behind the company’s decision to transition from NetScientific to EMV Capital, reflecting the integration of its portfolio and teams since the merger in 2020. He highlighted EMV Capital’s focus on deep tech and life sciences, particularly targeting companies with global ambitions.

“We provide value-creation services to help accelerate the growth of our portfolio companies,” Iliev explained. He also touched on the company’s unique investment model, which includes balance sheet investments, fund management, and syndicated investments, allowing EMV Capital to support early-stage companies in a capital-efficient manner. With over £100 million in assets under management (AUM), the rebrand signifies a new chapter for the firm as it positions itself for long-term success.